All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2020-01-20T14:31:54.000Z

Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?

By Alia Mohamed
Featured
Ruben A. Mesa
Jan 20, 2020
Share:

Bookmark this article

The MPN Hub were pleased to speak to Ruben Mesa, University of Texas Health Science Center, San Antonio, US, during the 61st American Society of Hematology Meeting & Exposition in Orlando, US. We asked: Is fedratinib a safe and efficacious treatment option for patients with primary myelofibrosis and low platelet counts?

Ruben Mesa discusses two major studies that assessed fedratinib (JAK2 inhibitor) in patients with primary myelofibrosis; the randomized phase III trial JAKARTA study and the JAKARTA2 second-line study. He discusses the safety and efficacy of both trials.

Is fedratinib a safe and efficacious treatment option for patients with PMF and low platelet counts?

More about...
ASH 2019FedratinibJAKARTAJAKARTA2Myeloproliferative neoplasmsPrimary myelofibrosisRuxolitinib

Related articles

Add bookmark

Treatment options in patients with myelofibrosis

Here, we summarize a presentation by Anthony Hunter from SOHO 2023, discussing how to appropriately choose and use JAK inhibitors for the treatment of patients with myelofibrosis.

Sep 25, 2023
Add bookmark

Treatment options in patients with myelofibrosis

Here, we summarize a presentation by Anthony Hunter from SOHO 2023, discussing how to appropriately choose and use JAK inhibitors for the treatment of...

Sep 25, 2023
Add bookmark

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?

The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the 61st American Society of Hematology (ASH) meeting...

Jan 20, 2020
Add bookmark

Is pacritinib safe and efficacious for patients with MF who failed ruxolitinib?

The MPN Hub were pleased to speak to Aaron Gerds, Cleveland Clinic Taussig Cancer Institute, Cleveland, US, during the...

Jan 20, 2020

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox